http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 05 Jun 2026 16:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+11++Filed+by%3A+Vasquez+Christian/26611543.html si-local-file:///var/storage/secattach/20260605/26611543.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+11++Filed+by%3A+Vasquez+Christian/26611543.html Fri, 05 Jun 2026 16:31:00 -0400 BCAB O.49397032 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+11++Filed+by%3A+Vasquez+Christian/26611543.html si-local-file:///var/storage/secattach/20260605/26611543.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+11++Filed+by%3A+Vasquez+Christian/26611543.html Fri, 05 Jun 2026 16:31:00 -0400 BCAB O.49397032 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+11++Filed+by%3A+Sievers+Eric/26611515.html si-local-file:///var/storage/secattach/20260605/26611515.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+11++Filed+by%3A+Sievers+Eric/26611515.html Fri, 05 Jun 2026 16:30:00 -0400 BCAB O.49397032 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+11++Filed+by%3A+Sievers+Eric/26611515.html si-local-file:///var/storage/secattach/20260605/26611515.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+11++Filed+by%3A+Sievers+Eric/26611515.html Fri, 05 Jun 2026 16:30:00 -0400 BCAB O.49397032 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+12++Filed+by%3A+SHORT+JAY+M+PHD/26611521.html si-local-file:///var/storage/secattach/20260605/26611521.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+12++Filed+by%3A+SHORT+JAY+M+PHD/26611521.html Fri, 05 Jun 2026 16:30:00 -0400 BCAB O.49397032 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+12++Filed+by%3A+SHORT+JAY+M+PHD/26611521.html si-local-file:///var/storage/secattach/20260605/26611521.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+12++Filed+by%3A+SHORT+JAY+M+PHD/26611521.html Fri, 05 Jun 2026 16:30:00 -0400 BCAB O.49397032 http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Dec+31/26598908.html si-local-file:///var/storage/secattach/20260603/26598908.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Dec+31/26598908.html Wed, 03 Jun 2026 16:10:00 -0400 BCAB O.49397032 http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Dec+31/26598908.html si-local-file:///var/storage/secattach/20260603/26598908.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++BioAtla%2C+Inc.+++++++++++++For%3A+Dec+31/26598908.html Wed, 03 Jun 2026 16:10:00 -0400 BCAB O.49397032 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++BioAtla%2C+Inc.++++++++++++++++++++++++/26598871.html si-local-file:///var/storage/secattach/20260603/26598871.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++BioAtla%2C+Inc.++++++++++++++++++++++++/26598871.html Wed, 03 Jun 2026 16:09:00 -0400 BCAB O.49397032 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++BioAtla%2C+Inc.++++++++++++++++++++++++/26598871.html si-local-file:///var/storage/secattach/20260603/26598871.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++BioAtla%2C+Inc.++++++++++++++++++++++++/26598871.html Wed, 03 Jun 2026 16:09:00 -0400 BCAB O.49397032 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++BioAtla%2C+Inc.+++++++++++++For%3A+Jun+03/26598836.html si-local-file:///var/storage/secattach/20260603/26598836.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++BioAtla%2C+Inc.+++++++++++++For%3A+Jun+03/26598836.html Wed, 03 Jun 2026 16:07:00 -0400 BCAB O.49397032 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++BioAtla%2C+Inc.+++++++++++++For%3A+Jun+03/26598836.html si-local-file:///var/storage/secattach/20260603/26598836.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++BioAtla%2C+Inc.+++++++++++++For%3A+Jun+03/26598836.html Wed, 03 Jun 2026 16:07:00 -0400 BCAB O.49397032 http://www.streetinsider.com/Corporate+News/Context+Therapeutics+amends+BioAtla+license+deal+for+CT-202+drug/26509859.html <p>Context Therapeutics Inc. (NASDAQ: CNTX) amended its exclusive license agreement with BioAtla Inc. (NASDAQ: BCAB) for CT-202, eliminating future milestone and royalty payments in exchange for $6.5 million in total payments.</p> <p>The biopharmaceutical company will pay $4.5 million upfront and an additional $2.0 million by August 1, 2026, according to a statement based on the press release. The amendment modifies the original license agreement dated September 23, 2024.</p> <p>CT-202 is a Nectin-4 x CD3 T cell engager bispecific antibody targeting Nectin-4, a protein overexpressed in bladder, colorectal, lung and breast tumors. The company expects to initiate a Phase 1 clinical trial for http://www.streetinsider.com/Corporate+News/Context+Therapeutics+amends+BioAtla+license+deal+for+CT-202+drug/26509859.html Mon, 18 May 2026 06:45:12 -0400 BCAB CNTX O.49397032 O.52485603 http://www.streetinsider.com/Corporate+News/Context+Therapeutics+amends+BioAtla+license+deal+for+CT-202+drug/26509859.html <p>Context Therapeutics Inc. (NASDAQ: CNTX) amended its exclusive license agreement with BioAtla Inc. (NASDAQ: BCAB) for CT-202, eliminating future milestone and royalty payments in exchange for $6.5 million in total payments.</p> <p>The biopharmaceutical company will pay $4.5 million upfront and an additional $2.0 million by August 1, 2026, according to a statement based on the press release. The amendment modifies the original license agreement dated September 23, 2024.</p> <p>CT-202 is a Nectin-4 x CD3 T cell engager bispecific antibody targeting Nectin-4, a protein overexpressed in bladder, colorectal, lung and breast tumors. The company expects to initiate a Phase 1 clinical trial for http://www.streetinsider.com/Corporate+News/Context+Therapeutics+amends+BioAtla+license+deal+for+CT-202+drug/26509859.html Mon, 18 May 2026 06:45:12 -0400 BCAB CNTX O.49397032 O.52485603 http://www.streetinsider.com/Corporate+News/Context+Therapeutics+amends+BioAtla+license+deal+for+CT-202+drug/26509859.html <p>Context Therapeutics Inc. (NASDAQ: CNTX) amended its exclusive license agreement with BioAtla Inc. (NASDAQ: BCAB) for CT-202, eliminating future milestone and royalty payments in exchange for $6.5 million in total payments.</p> <p>The biopharmaceutical company will pay $4.5 million upfront and an additional $2.0 million by August 1, 2026, according to a statement based on the press release. The amendment modifies the original license agreement dated September 23, 2024.</p> <p>CT-202 is a Nectin-4 x CD3 T cell engager bispecific antibody targeting Nectin-4, a protein overexpressed in bladder, colorectal, lung and breast tumors. The company expects to initiate a Phase 1 clinical trial for http://www.streetinsider.com/Corporate+News/Context+Therapeutics+amends+BioAtla+license+deal+for+CT-202+drug/26509859.html Mon, 18 May 2026 06:45:12 -0400 BCAB CNTX O.49397032 O.52485603 http://www.streetinsider.com/Corporate+News/Context+Therapeutics+amends+BioAtla+license+deal+for+CT-202+drug/26509859.html <p>Context Therapeutics Inc. (NASDAQ: CNTX) amended its exclusive license agreement with BioAtla Inc. (NASDAQ: BCAB) for CT-202, eliminating future milestone and royalty payments in exchange for $6.5 million in total payments.</p> <p>The biopharmaceutical company will pay $4.5 million upfront and an additional $2.0 million by August 1, 2026, according to a statement based on the press release. The amendment modifies the original license agreement dated September 23, 2024.</p> <p>CT-202 is a Nectin-4 x CD3 T cell engager bispecific antibody targeting Nectin-4, a protein overexpressed in bladder, colorectal, lung and breast tumors. The company expects to initiate a Phase 1 clinical trial for http://www.streetinsider.com/Corporate+News/Context+Therapeutics+amends+BioAtla+license+deal+for+CT-202+drug/26509859.html Mon, 18 May 2026 06:45:12 -0400 BCAB CNTX O.49397032 O.52485603 http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html <p align="center"><em>Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license</em></p> <p align="center"><em>Phase 1 initiation for CT-202 trial expected in third quarter of 2026</em></p> <p>PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced the amendment of the Company’s exclusive license agreement, dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company’s http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html Mon, 18 May 2026 06:45:00 -0400 BCAB CNTX O.49397032 O.52485603 http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html <p align="center"><em>Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license</em></p> <p align="center"><em>Phase 1 initiation for CT-202 trial expected in third quarter of 2026</em></p> <p>PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced the amendment of the Company’s exclusive license agreement, dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company’s http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html Mon, 18 May 2026 06:45:00 -0400 BCAB CNTX O.49397032 O.52485603 http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html <p align="center"><em>Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license</em></p> <p align="center"><em>Phase 1 initiation for CT-202 trial expected in third quarter of 2026</em></p> <p>PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced the amendment of the Company’s exclusive license agreement, dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company’s http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html Mon, 18 May 2026 06:45:00 -0400 BCAB CNTX O.49397032 O.52485603 http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html <p align="center"><em>Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license</em></p> <p align="center"><em>Phase 1 initiation for CT-202 trial expected in third quarter of 2026</em></p> <p>PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced the amendment of the Company’s exclusive license agreement, dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company’s http://www.streetinsider.com/Press+Releases/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html Mon, 18 May 2026 06:45:00 -0400 BCAB CNTX O.49397032 O.52485603 http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html <p align="center"><em>Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license</em></p> <p align="center"><em>Phase 1 initiation for CT-202 trial expected in third quarter of 2026</em></p> <p>PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced the amendment of the Company’s exclusive license agreement, dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company’s http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html Mon, 18 May 2026 06:45:00 -0400 BCAB CNTX O.49397032 O.52485603 http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html <p align="center"><em>Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license</em></p> <p align="center"><em>Phase 1 initiation for CT-202 trial expected in third quarter of 2026</em></p> <p>PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced the amendment of the Company’s exclusive license agreement, dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company’s http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html Mon, 18 May 2026 06:45:00 -0400 BCAB CNTX O.49397032 O.52485603 http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html <p align="center"><em>Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license</em></p> <p align="center"><em>Phase 1 initiation for CT-202 trial expected in third quarter of 2026</em></p> <p>PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced the amendment of the Company’s exclusive license agreement, dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company’s http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html Mon, 18 May 2026 06:45:00 -0400 BCAB CNTX O.49397032 O.52485603 http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html <p align="center"><em>Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license</em></p> <p align="center"><em>Phase 1 initiation for CT-202 trial expected in third quarter of 2026</em></p> <p>PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced the amendment of the Company’s exclusive license agreement, dated September 23, 2024, with BioAtla, Inc. (Nasdaq: BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company’s http://www.streetinsider.com/Globe+Newswire/Context+Therapeutics+Enters+into+License+Agreement+Amendment+with+BioAtla+for+CT-202/26509854.html Mon, 18 May 2026 06:45:00 -0400 BCAB CNTX O.49397032 O.52485603 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+31/26505157.html si-local-file:///var/storage/secattach/20260515/26505157.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++BioAtla%2C+Inc.+++++++++++++For%3A+Mar+31/26505157.html Fri, 15 May 2026 16:10:00 -0400 BCAB O.49397032